ESR1 and breast carcinoma: Clinically, patients with ER+ breast cancer are treated with either selective ER modulators such as tamoxifen, which binds to and blocks ER, or selective estrogen degraders such as fulvestrant, which binds ER and induces its proteasomal degradation.